Management of arthropathy in inflammatory bowel diseases

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 2, 2015, Pages 65-77

  Peluso, Rosario ^a   Manguso, Francesco ^b   Vitiello, Maria ^a   Iervolino, Salvatore ^c   Minno, Matteo Nicola Dario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c IRCCS   (Italy)

Author keywords

Enteropathic arthritis; Inflammatory bowel disease; TNF inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; SULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ALLERGIC PNEUMONITIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; BURNING SENSATION; CLINICAL FEATURE; COLITIS; COLON RESECTION; CROHN DISEASE; CYANOSIS; DACTYLITIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENTHESITIS; ERYTHEMA; EXERCISE; FEVER; FLU LIKE SYNDROME; HEART FAILURE; HEMOLYSIS; HEPATITIS; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL NEPHRITIS; INTESTINE ULCER; JOINT INJURY; JOINT STIFFNESS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; PAIN; PANCREATITIS; PERFORATION; PHYSIOTHERAPY; PNEUMONIA; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RETICULOCYTOSIS; REVIEW; RISK BENEFIT ANALYSIS; SACROILIITIS; SPINAL PAIN; SPONDYLARTHRITIS; SPONDYLITIS; SWIMMING; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84923641591     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622314563929     Document Type: Review

References (114)

1. Abi Karam G. Awada H. Nasr F. Uthman I. (2003) Ileal pouchitis and arthritis. Semin Arthritis Rheum 33: 215.
2. Ampuero J. Rojas-Feria M. Castro-Fernández M. Cano C. Romero-Gómez M. (2014). Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol 29 (2): 291–295.
3. Amrami K. (2012). Imaging of the seronegative spondyloarthopathies. Radiol Clin North Am 50: 841–854.
4. Ardelean D. Gonska T. Wires S. Cutz E. Griffiths A. Harvey E. et al. (2010) Severe ulcerative colitis after rituximab therapy. Pediatrics 126: 243–246.
5. Atteno M. Peluso R. Costa L. Padula S. Iervolino S. Caso F. et al. (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29: 399–403.
6. Atzeni F. Ardizzone S. Bertani L. Antivalle M. Batticciotto A. Sarzi-Puttini P. (2009) Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol 15: 2469–2471.
7. Baert F. Noman M. Vermeire S. van Assche G. D'Haens G. Carbonez A. et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608.
8. Baeten D. de Keyser K. Mielants H. Veys E. (2002) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 16: 537–549.
9. Balbir-Gurman A. Schapira D. Nahir M. (2001) Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin Arthritis Rheum 30: 242–248.
10. Baraliakos X. Braun J. (2012) Biologic therapies for spondyloarthritis: what is new? Curr Rheumatol Rep 14: 422–427.
11. Barrie A. Regueiro M. (2007) Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 13: 1424–1429.
12. Bergfeldt L. (1997) HLA-B27-associated cardiac disease. Ann Intern Med 127: 621–629.
13. Blumberg B. Bunim J. Calkins E. Pirani C. Zvaifler N. (1964) Aranomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 7: 93–97.
14. Bongartz T. Sutton A. Sweeting M. Buchan I. Matteson E. Montori V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285.
15. Braun J. Baraliakos X. Hermann K. Deodhar A. van der Heijde D. Inman R. et al. (2014) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73: 1107–1113.
16. Braun J. Baraliakos X. Listing J. Davis J. van der Heijde D. Haibel H. et al. (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57: 639–647.
17. Braun J. van den Berg R. Baraliakos X. Boehm H. Burgos-Vargas R. Collantes-Estevez E. et al. (2011) 2010 update of the ASAS / EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70: 896–904.
18. Bruner V. Atteno M. Spanò A. Scarpa R. Peluso R. (2014) Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis 6: 92–101.
19. Bywaters E. Ansell B. (1958) Arthritis associated with ulcerative colitis; a clinical and pathological study. Ann Rheum Dis 2: 169–183.
20. Carbonnel F. (2011) Methotrexate: a drug of the future in ulcerative colitis? Curr Drug Targets 12: 1413–1416.
21. Chaparro M. Ordás I. Cabré E. Garcia-Sanchez V. Bastida G. Peñalva M. et al. (2013) Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 19: 1404–1410.
22. Clegg D. Reda D. Abdellatif M. (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42: 2325–2329.
23. Cohen R. Stein R. Hanauer S. (1999) Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 94: 1587–1592.
24. Colombel J. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Panaccione R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65.
25. Cummings J. Keshav S. Travis S. (2008) Medical management of Crohn's disease. BMJ 336: 1062–1066.
26. Dagfinrud H. Kvien T. Hagen K. (2005) The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 32: 1899–1906.
27. Das K. Eastwood M. McManus J. Sircus W. (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289: 491–495.
28. de Keyser F. van Damme N. de Vos M. Mielants H. Veys E. (2000) Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 49: 47–54.
29. Devlin S. Panaccione R. (2008) Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 8: 1011–1019.
30. Dignass A. van Assche G. Lindsay J. Lemann M. Soderholm J. Colombel J. et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4: 28–62.
31. Di Minno M. Iervolino S. Lupoli R. Russolillo A. Coppola A. Peluso R. et al. (2012 a) Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 38: 497–505.
32. Di Minno M. Iervolino S. Peluso R. Scarpa R. Di Minno G. (2012 b) Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 39: 334–336.
33. Dissanayake A. Truelove S. (1973) Acontrolled therapeutic trial of long term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 12: 923–926.
34. Dougados M. Dijkmans B. Khan M. Maksymowych W. van der Linden S. Brandt J. (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61(Suppl 3): iii40–iii50.
35. Ellman M. Hanauer S. Sitrin M. Cohen R. (2001) Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 7: 67–71.
36. Farr M. Tunn E. Symmons D. Scott D. Bacon P. (1989) Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 28: 134–138.
37. Feagan B. Alfadhli A. (2004) Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 33: 407–420.
38. Ferraz M. Tugwell P. Goldsmith C. Atra E. (1990) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17: 1482–1486.
39. Generini S. Giacomelli R. Fedi R. Fulminis A. Pignone A. Frieri G. et al. (2004) Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63: 1664–1669.
40. Genovese M. McKay J. Nasonov E. Mysler E. Da Silva N. Alecock E. et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 58: 2968–2980.
41. Goetz M. Atreya R. Ghalibafian M. Galle P. Neurath M. (2007) Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 13: 1365–1368.
42. Gossec L. Smolen J. Gaujoux-Viala C. Ash Z. Marzo-Ortega H. van der Heijde D. FitzGerald O. et al. (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71: 4–12.
43. Haibel H. Rudwaleit M. Braun J. Sieper J. (2005) Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64: 124–126.
44. Hanauer S. Feagan B. Lichtenstein G. Mayer L. Schreiber S. Colombel J. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
45. Hanauer S. Panes J. Colombel J. Bloomfield R. Schreiber S. Sandborn W. (2010) Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 32: 384–393.
46. Haraoui B. Krelenbaum M. (2009) Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 39: 176–181.
47. Herfarth H. Obermeier F. Andus T. Rogler G. Nikolaus S. Kuehbacher T. et al. (2002) Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 97: 2688–2690.
48. Hopkinson N. Saiz Garcia F. Gumpel J. (1989) Haematological side-effects of sulphasalazine in inflammatory arthritis. Br J Rheumatol 28: 414–417.
49. Inman R. Davis J. Jr Heijde D. Diekman L. Sieper J. Kim S. et al. (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58: 3402–3412.
50. Jarnerot G. Hertervig E. Friis-Liby I. Blomquist L. Karlen P. Granno C. et al. (2005) Infliximab as rescue therapy in severe to moderately ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805–1811.
51. Kandiel A. Fraser A. Korelitz B. Brensinger C. Lewis J. (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121–1125.
52. Katz S. (2005) Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 39: 557–569.
53. Kaufman H. Fischer A. Carroll M. Becker J. (1996) Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Dis Colon Rectum 39: 705–710.
54. Kaufman I. Caspi D. Yeshurun D. Dotan I. Yaron M. Elkayam O. (2005) The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 25: 406–410.
55. Khan K. Dubinsky M. Ford A. Ullman T. Talley N. Moayyedi P. (2011) Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106: 630–642.
56. Lambert R. Pedersen S. Maksymowych W. Chiowchanwisawakit P. Østergaard M. (2009) Active inflammatory lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis – definitions, assessment system and reference image set. J Rheumatol 36(Suppl. 84): 3–17.
57. Lichtiger S. Binion D. Wolf D. Present D. Bensimon A. Wu E. et al. (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32: 1228–1239.
58. Manguso F. Sanges M. Staiano T. Gargiulo S. Nastro P. Gargano D. et al. (2004) Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 99: 327–334.
59. Manguso F. Staiano T. Astarita C. Scarpa R. Peluso R. Gargano D. et al. (2005) Consecutive occurrence of rhinoconjunctivitis, seronegative spondyloarthritis and pyoderma gangrenosum in a patient with ulcerative colitis. Int J Colorectal Dis 20: 79–80.
60. Marzo-Ortega H. McGonagle D. O'Connor P. Emery P. (2003) Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 62: 74–76.
61. McBride J. King M. Baikie A. Crean G. Sircus W. (1963) Ankylosing spondylitis and chronic inflammatory diseases of the intestines. Br Med J 2: 483–486.
62. McKenna K. Burrows D. (1994) Leucopenia, thrombocytopenia and lymphadenopathy associated with sulphasalazine. Clin Exp Dermatol 19: 419–420.
63. McLean L. Shea-Donohue T. Cross R. (2012) Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 4: 883–898.
64. Menghini V. Arora A. (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76: 84–86.
65. Mohan N. Edwards E. Cupps T. Oliverio P. Sandberg G. Crayton H. et al. (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862–2869.
66. Monterubbianesi R. Aratari A. Armuzzi A. Daperno M. Biancone L. Cappello M. et al. (2014) Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 8: 852–858.
67. Moum B. Konopski Z. Tufteland K. Jahnsen J. (2007) Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 13: 1584–1586.
68. Mozaffari S. Nikfar S. Abdolghaffari A. Abdollahi M. (2014) New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther 14: 583–600.
69. Nikfar S. Rahimi R. Rezaie A. Abdollahi M. (2009) A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 54: 1157–1170.
70. Nishimoto N. Ito K. Takagi N. (2010) Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 20: 222–232.
71. O'Brien J. (2000) Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 95: 1859–1861.
72. Oikonomou K. Kapsoritakis A. Eleftheriadis T. Stefanidis I. Potamianos S. (2011) Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 17: 1034–1045.
73. Olivieri I. Cantini F. Castiglione F. Felice C. Gionchetti P. Orlando A. et al. (2014) Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 13: 822–830.
74. Orchard T. Wordsworth B. Jewell D. (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42: 387–391.
75. Orlando A. Armuzzi A. Papi C. Annese V. Ardizzone S. Biancone L. et al. (2011) The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 43: 1–20.
76. Ostendorf B. Specker C. Schneider M. (1998) Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis. J Clin Rheumatol 4: 129–136.
77. Padovan M. Castellino G. Govoni M. Trotta F. (2006) The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int 26: 953–958.
78. Peluso R. Atteno M. Iervolino S. Bruner V. Caso F. Costa L. et al. (2009) Methotrexate in the treatment of peripheral arthritis in ulcerative colitis. Reumatismo 61: 15–20.
79. Peluso R. Cafaro G. Di Minno A. Iervolino S. Ambrosino P. Lupoli G. et al. (2013 a). Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol 32: 743–753.
80. Peluso R. Di Minno M. Bruner V. Soscia E. Castiglione F. Manguso F. et al. (2012) Discovertebral erosions in patients with enteropathic spondyloarthritis. J Rheumatol 39: 2332–2340.
81. Peluso R. Di Minno M. Iervolino S. Manguso F. Tramontano G. Ambrosino P. et al. (2013 b). Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013: 631408.
82. Peluso R. Iervolino S. Vitiello M. Bruner V. Ambrosino P. Manguso F. et al. (2014) Articular and other immune-mediated extra-intestinal manifestations in inflammatory bowel diseases. Eur J Inflamm 12: 251–259.
83. Present D. Rutgeerts P. Targan S. Hanauer S. Mayer L. van Hogezand R. et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398–1405.
84. Ransford R. Langman M. (2002) Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 51: 536–553.
85. Regueiro M. (2000) Update in medical treatment of Crohn's disease. J Clin Gastroenterol 31: 282–291.
86. Rispo A. Scarpa R. Di Girolamo E. Cozzolino A. Lembo G. Atteno M. et al. (2005) Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 34: 387–391.
87. Ritchlin C. Kavanaugh A. Gladman D. Mease P. Helliwell P. Boehncke W. et al. (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68: 1387–1394.
88. Roychowdhury B. Bintley-Bagot S. Bulgen D. Thompson R. Tunn E. Moots R. (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41: 1330–1332.
89. Sakuraba A. Keyashian K. Correia C. Melek J. Cohen R. Hanauer S. Rubin D. (2013) Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 19: 621–626.
90. Sandborn W. Abreu M. D'Haens G. Colombel J. Vermeire S. Mitchev K. et al. (2010) Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8: 688–695.
91. Sandborn W. Feagan B. Fedorak R. Scherl E. Fleisher M. Katz S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130–1141.
92. Sandborn W. Feagan B. Marano C. Zhang H. Strauss R. Johanns J. et al. (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 96–109.
93. Sandborn W. Feagan B. Stoinov S. Honiball P. Rutgeerts P. Mason D. et al. (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228–238.
94. Sandborn W. Hanauer S. Katz S. Safdi M. Wolf D. Baerg R. et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094.
95. Sandborn W. Rutgeerts P. Feagan B. Reinisch W. Olson A. Johanns J. et al. (2009) Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137: 1250–1260.
96. Sandborn W. Stenson W. Brynskov J. Lorenz R. Steidle G. Robbins J. et al. (2006) Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4: 203–211.
97. Sanduzzi A. Bocchino M. Atteno M. Costa L. Ponticiello A. Matarese A. et al. (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol 89: 82–85.
98. Smale S. Natt R. Orchard T. Russell A. Bjarnason I. (2001) Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 44: 2728–2736.
99. Soscia E. Scarpa R. Cimmino M. Atteno M. Peluso R. Sirignano C. et al. (2009) Magnetic resonance imaging of nail unit in psoriatic arthritis. J Rheumatol 83: 42–45.
100. Steinberg V. Storey G. (1957) Ankylosing spondylitis and chronic inflammatory lesions of the intestines. Br Med J 2: 1157–1159.
101. Stewart J. Ansell B. (1963) Ankylosing spondylitis associated with regional enteritis. Gastroenterology 45: 265–268.
102. Sutherland L. Macdonald J. (2006) Oral 5-aminosalicylic acid formaintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2: CD000544.
103. Tebbutt N. Giraud A. Inglese M. Jenkins B. Waring P. Clay F. et al. (2002) Reciprocal regulation of gastrointestinal homeostasis by SHP 2 and STAT-mediated trefoil gene activation in gp 130 mutant mice. Nat Med 8: 1089–1097.
104. Thomson G. McKibbon C. Inman R. (1994) Mesalamine therapy in Reiter's syndrome. J Rheumatol 21: 570–572.
105. van den Bosch F. Kruithof E. Vos M. Keyser F. Mielants H. (2000) Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 356: 1821–1822.
106. van der Heijde D. Kivitz A. Schiff M. Sieper J. Dijkmans B. Braun J. et al. (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54: 2136–2146.
107. van der Heijde D. Sieper J. Maksymowych W. Dougados M. Burgos-Vargas R. Landewe R. et al. (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70: 905–908.
108. van Dieren J. Kuipers E. Samsom J. Nieuwenhuis E. van der Woude C. (2006) Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 12: 311–327.
109. Velayos F. Loftus E. Jr Jess T. Harmsen W. Bida J. Zinsmeister A. et al. (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology 130: 1941–1949.
110. Voulgari P. (2011) Rheumatological manifestations in inflammatory bowel disease. Ann Gastroenterol 24: 173–180.
111. Williams H. Walker D. Orchard T. (2008) Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 10: 597–605.
112. Wright V. Moll J. (1976) Seronegative Polyarthritis. Amsterdam: North Holland Publishing Company.
113. Yarur A. Deshpande A. Pechman D. Tamariz L. Abreu M. Sussman D. (2011) Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 106: 741–747.
114. Yorulmaz E. Adali G. Yorulmaz H. Ulasoglu C. Tasan G. Tuncer I. (2011) Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J Gastroenterol 17: 376–382.